ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 82 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2014. The put-call ratio across all filers is 0.71 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2017 | $3,053,000 | -18.1% | 57,314 | -4.5% | 0.01% | -20.0% |
Q2 2017 | $3,728,000 | +13.8% | 60,023 | +24.2% | 0.02% | +15.4% |
Q1 2017 | $3,276,000 | -5.6% | 48,338 | -2.1% | 0.01% | -7.1% |
Q4 2016 | $3,472,000 | -0.5% | 49,387 | +0.4% | 0.01% | -6.7% |
Q3 2016 | $3,490,000 | -8.1% | 49,200 | -36.6% | 0.02% | -6.2% |
Q2 2016 | $3,796,000 | -31.7% | 77,610 | -11.2% | 0.02% | -33.3% |
Q1 2016 | $5,555,000 | -39.1% | 87,371 | +7.5% | 0.02% | -38.5% |
Q4 2015 | $9,121,000 | +13.5% | 81,305 | -2.5% | 0.04% | +8.3% |
Q3 2015 | $8,033,000 | +5.9% | 83,410 | +12.5% | 0.04% | +16.1% |
Q2 2015 | $7,589,000 | +110.6% | 74,119 | +27.7% | 0.03% | +106.7% |
Q1 2015 | $3,604,000 | +55.9% | 58,050 | +10.2% | 0.02% | +50.0% |
Q4 2014 | $2,312,000 | -12.3% | 52,699 | +13.2% | 0.01% | -9.1% |
Q3 2014 | $2,635,000 | +234.4% | 46,547 | +165.1% | 0.01% | +266.7% |
Q2 2014 | $788,000 | +59.2% | 17,555 | +73.2% | 0.00% | +50.0% |
Q1 2014 | $495,000 | – | 10,133 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
First Light Asset Management, LLC | 213,887 | $29,608,000 | 2.19% |
Rock Springs Capital Management LP | 566,500 | $78,421,000 | 1.66% |
FEDERATED HERMES, INC. | 4,280,528 | $592,554,000 | 1.21% |
AtonRa Partners | 17,646 | $2,443,000 | 1.20% |
EMERALD MUTUAL FUND ADVISERS TRUST | 218,390 | $30,232,000 | 1.05% |
EMERALD ADVISERS, LLC | 226,875 | $31,406,000 | 1.04% |
Atika Capital Management LLC | 89,000 | $12,319,000 | 0.96% |
Capital Impact Advisors, LLC | 25,582 | $3,541,000 | 0.87% |
JGP Global Gestao de Recursos Ltda. | 1,586 | $220,000 | 0.83% |
CAPITAL INTERNATIONAL LTD /CA/ | 79,742 | $11,039,000 | 0.64% |